Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irreversible Electroporation (IRE) of Recurrent Pelvic Tumors: the PELFIRE Study.

NCT07782164 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT07782164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07782164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irreversible Electroporation (IRE) of Recurrent Pelvic Tumors: the PELFIRE Study.
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Observational
Overall status
Recruiting
Start date
April 18, 2025
Completion date
July 31, 2028
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, bladder cancer, cervical cancer, colorectal carcinoma, lung cancer (including metastatic cancer), neoplasm recurrence, local, ovarian cancer, prostate cancer, renal cancer